Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses

Hongxun Sang, Vladimir M. Pisarev, Jennifer Chavez, Simon Robinson, Yajun Guo, Lori Hatcher, Corey Munger, Cathy B. Talmadge, Joyce C Solheim, Rakesh K Singh, James E Talmadge

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Transfection of tumors with tumor-associated antigens (Ags) or cytokines can increase immunogenicity and slow down tumor growth. However, the effect of cotransfection with genes that encode a tumor-associated Ag, such as the tumor suppressor gene p53, and a cytokine has been rarely investigated. We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. Immunization with irradiated 4T1 cells transfected with Flt3L induced DC infiltration of the immunization site and significantly increased the antitumor T-cell responses. Further, immunization with irradiated 4T1 cells cotransfected with p53 and Flt3L significantly increased p53-specific immune responses, as compared to vaccination with 4T1 cells transfected with either Flt3L or p53 alone. These responses included increased activity against clone 66 (Cl-66), a sister tumor to 4T1 with high murine mutant p53 expression levels. Challenge with Cl-66 revealed that immunization with irradiated 4T1-Flt3L-p53 cells significantly slowed growth, prolonged survival, and resulted in complete remissions. Further, immunization with irradiated 4T1-Flt3L also slowed Cl-66 growth, although to a lesser extent than 4T1-Flt3L-p53. We suggest that immunization with DCs transfected with the Flt3L transgene and a tumor Ag may potentially heighten T-cell responses and therapeutic activity.

Original languageEnglish (US)
Pages (from-to)427-437
Number of pages11
JournalCancer Gene Therapy
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2005

Fingerprint

Adenocarcinoma
Breast
Immunization
Neoplasms
Clone Cells
Growth
Dendritic Cells
Transfection
Cytokines
T-Lymphocytes
flt3 ligand protein
Null Lymphocytes
Neoplasm Antigens
Tumor Suppressor Genes
Transgenes
Intercellular Signaling Peptides and Proteins
Vaccination
Breast Neoplasms
Injections
Genes

Keywords

  • Dendritic cell
  • Flt3L
  • Mammary tumor
  • Vaccine
  • p53

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses. / Sang, Hongxun; Pisarev, Vladimir M.; Chavez, Jennifer; Robinson, Simon; Guo, Yajun; Hatcher, Lori; Munger, Corey; Talmadge, Cathy B.; Solheim, Joyce C; Singh, Rakesh K; Talmadge, James E.

In: Cancer Gene Therapy, Vol. 12, No. 4, 01.04.2005, p. 427-437.

Research output: Contribution to journalArticle

Sang, Hongxun ; Pisarev, Vladimir M. ; Chavez, Jennifer ; Robinson, Simon ; Guo, Yajun ; Hatcher, Lori ; Munger, Corey ; Talmadge, Cathy B. ; Solheim, Joyce C ; Singh, Rakesh K ; Talmadge, James E. / Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses. In: Cancer Gene Therapy. 2005 ; Vol. 12, No. 4. pp. 427-437.
@article{f54e80e1ead34da29ae816034efc60f6,
title = "Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses",
abstract = "Transfection of tumors with tumor-associated antigens (Ags) or cytokines can increase immunogenicity and slow down tumor growth. However, the effect of cotransfection with genes that encode a tumor-associated Ag, such as the tumor suppressor gene p53, and a cytokine has been rarely investigated. We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100{\%} of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. Immunization with irradiated 4T1 cells transfected with Flt3L induced DC infiltration of the immunization site and significantly increased the antitumor T-cell responses. Further, immunization with irradiated 4T1 cells cotransfected with p53 and Flt3L significantly increased p53-specific immune responses, as compared to vaccination with 4T1 cells transfected with either Flt3L or p53 alone. These responses included increased activity against clone 66 (Cl-66), a sister tumor to 4T1 with high murine mutant p53 expression levels. Challenge with Cl-66 revealed that immunization with irradiated 4T1-Flt3L-p53 cells significantly slowed growth, prolonged survival, and resulted in complete remissions. Further, immunization with irradiated 4T1-Flt3L also slowed Cl-66 growth, although to a lesser extent than 4T1-Flt3L-p53. We suggest that immunization with DCs transfected with the Flt3L transgene and a tumor Ag may potentially heighten T-cell responses and therapeutic activity.",
keywords = "Dendritic cell, Flt3L, Mammary tumor, Vaccine, p53",
author = "Hongxun Sang and Pisarev, {Vladimir M.} and Jennifer Chavez and Simon Robinson and Yajun Guo and Lori Hatcher and Corey Munger and Talmadge, {Cathy B.} and Solheim, {Joyce C} and Singh, {Rakesh K} and Talmadge, {James E}",
year = "2005",
month = "4",
day = "1",
doi = "10.1038/sj.cgt.7700809",
language = "English (US)",
volume = "12",
pages = "427--437",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses

AU - Sang, Hongxun

AU - Pisarev, Vladimir M.

AU - Chavez, Jennifer

AU - Robinson, Simon

AU - Guo, Yajun

AU - Hatcher, Lori

AU - Munger, Corey

AU - Talmadge, Cathy B.

AU - Solheim, Joyce C

AU - Singh, Rakesh K

AU - Talmadge, James E

PY - 2005/4/1

Y1 - 2005/4/1

N2 - Transfection of tumors with tumor-associated antigens (Ags) or cytokines can increase immunogenicity and slow down tumor growth. However, the effect of cotransfection with genes that encode a tumor-associated Ag, such as the tumor suppressor gene p53, and a cytokine has been rarely investigated. We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. Immunization with irradiated 4T1 cells transfected with Flt3L induced DC infiltration of the immunization site and significantly increased the antitumor T-cell responses. Further, immunization with irradiated 4T1 cells cotransfected with p53 and Flt3L significantly increased p53-specific immune responses, as compared to vaccination with 4T1 cells transfected with either Flt3L or p53 alone. These responses included increased activity against clone 66 (Cl-66), a sister tumor to 4T1 with high murine mutant p53 expression levels. Challenge with Cl-66 revealed that immunization with irradiated 4T1-Flt3L-p53 cells significantly slowed growth, prolonged survival, and resulted in complete remissions. Further, immunization with irradiated 4T1-Flt3L also slowed Cl-66 growth, although to a lesser extent than 4T1-Flt3L-p53. We suggest that immunization with DCs transfected with the Flt3L transgene and a tumor Ag may potentially heighten T-cell responses and therapeutic activity.

AB - Transfection of tumors with tumor-associated antigens (Ags) or cytokines can increase immunogenicity and slow down tumor growth. However, the effect of cotransfection with genes that encode a tumor-associated Ag, such as the tumor suppressor gene p53, and a cytokine has been rarely investigated. We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. Immunization with irradiated 4T1 cells transfected with Flt3L induced DC infiltration of the immunization site and significantly increased the antitumor T-cell responses. Further, immunization with irradiated 4T1 cells cotransfected with p53 and Flt3L significantly increased p53-specific immune responses, as compared to vaccination with 4T1 cells transfected with either Flt3L or p53 alone. These responses included increased activity against clone 66 (Cl-66), a sister tumor to 4T1 with high murine mutant p53 expression levels. Challenge with Cl-66 revealed that immunization with irradiated 4T1-Flt3L-p53 cells significantly slowed growth, prolonged survival, and resulted in complete remissions. Further, immunization with irradiated 4T1-Flt3L also slowed Cl-66 growth, although to a lesser extent than 4T1-Flt3L-p53. We suggest that immunization with DCs transfected with the Flt3L transgene and a tumor Ag may potentially heighten T-cell responses and therapeutic activity.

KW - Dendritic cell

KW - Flt3L

KW - Mammary tumor

KW - Vaccine

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=20144381065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144381065&partnerID=8YFLogxK

U2 - 10.1038/sj.cgt.7700809

DO - 10.1038/sj.cgt.7700809

M3 - Article

VL - 12

SP - 427

EP - 437

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 4

ER -